Who
Eric L. Keller
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Retension Pharmaceuticals.
In numbers
- Trades disclosed
- 6
- Buys
- 1
- Sells
- 0
- Bought
- $250K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Oct 2026
- Last trade
- 13 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $250K20,800 at $12.00 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —9,662 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —31,368 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —255,174 at $0.00 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,662 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —31,368 | filing |
News
Retension Pharmaceuticals IPO priced at $12, raising $45 millionRTSN · 247wallst.com · 9 Oct 2026
0 headlines in the last 90 days name Eric L. Keller; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.